Table 1.
Distinct features of breast cancer based on molecular histotypes for U.S. women.
| Molecular Subtypes | Luminal A | Luminal B | HER2 Positive |
Triple Negative | Inflammatory Breast Cancer |
|---|---|---|---|---|---|
| % of Breast Cancers (U.S. Women) [12] |
11% | 73% | 4% | 12% | Unknown |
| Receptor Expression | ER+ PR+ HER2+ |
ER+ PR± HER2- |
ER- PR- HER2+ |
ER- PR- HER2- |
ER-, PR-, HER2+ TNBC |
| Histological Grade | Low | Intermediate | High | High | High |
| Prognosis | Good | Intermediate | Poor | Poor | Poor |
| Ki67 by IHC | Low | High | High | High | High |
| Response to Treatment |
Endocrine therapy: anti-estrogen aromatase inhibitors—Anastrozole Exemestrozole Letrozole |
Endocrine therapy: anti-estrogen aromatase inhibitors—Anastrozole Exemestrozole Letrozole |
HER2-targeted drugs: Trastuzumab Pertuzumab Neratinib |
Treatment: Taxanes— Paclitaxel Docetaxel Anthracyclines Doxorubicon 5-flurouracil |
Treatment: HER2+ targeted therapy |